Join $CGTX at 8:30am today, November 5 for a third quarter financial results conference call. The webcast may be accessed from our website: ir.cogrx.com/events. Dial-in information is as follows:
Toll Free (US & Canada): 1-800-715-9871
US/International Toll: 1-646-307-1963
Conference ID: 9023814
This November, we recognize #NationalFamilyCaregiversMonth. In the United States, there are 63 million family caregivers who provide care for loved ones - nearly all without pay. Almost 12 million care for loved ones with dementias such as #Alzheimers disease and #dementia with Lewy bodies.
At $CGTX we are committed to learning from people living with #DementiaWithLewyBodies as well as their caregivers as we advance our lead candidate, #zervimesine towards a Phase 3 trial.
Learn more about resources that are available to caregivers through the Alzheimer's Association: buff.ly/Mk0Vqh7.
#CareConnectsUs #NFCMonth #DementiaCare #DementiaSupport
During this year's #LewyBodyDementia Awareness Month, we will focus on the concept that #UnderstandingChangesEverything.
Did you know that hallucinations are common in Lewy body dementias (#ParkinsonsDiseaseDementia and #DementiawithLewyBodies)? Hallucinations are actually a core diagnostic feature of DLB and may be one of the first symptoms to emerge. They can start as an unseen presence or the feeling of something touching you. Then as DLB progresses, the hallucinations may evolve to shadowy images or vivid visual hallucinations.
If you're interested in learning more, the Lewy Body Society has information and tips on their website: lewybody.org/information-and…
#LewyStrong #ClinicalResearch #Dementia #DementiaCare #DementiaSupport #DYK #LewyBodyAwarenessMonth
$CGTX and #FDA have aligned on key elements of a Phase 3 study in #DementiaWithLewyBodies (DLB) including patient selection, dose, duration, and endpoints. Read the #pressrelease here: buff.ly/EJABujD
The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral #zervimesine or placebo for nine months.
#BiotechInnovation #LewyStrong #ClinicalResearch #Dementia #DementiaCare #DementiaSupport
During this year's #LewyBodyDementia Awareness Month, we will focus on the concept that #UnderstandingChangesEverything.
Did you know that autonomic dysfunction is common is Lewy body dementias (#ParkinsonsDiseaseDementia and #DementiawithLewyBodies)? Disruptions in a person's autonomic system could present as bouts of feeling very hot or cold, dizziness, or constipation. In some, autonomic dysfunction can appear years before memory or movement problems. Understanding these symptoms might lead to a diagnosis earlier in the disease.
If you're interested in learning more, the @LBDA presented a webinar on changes in the autonomic system in LBD that you can find on YouTube : youtube.com/watch?v=750lQkIA…
#LewyStrong #ClinicalResearch #Dementia #DementiaCare #DementiaSupport #DYK #LewyBodyAwarenessMonth
This morning, $CGTX announced that the United States Patent and Trademark Office (USPTO) has granted the company a patent covering a novel crystalline form of zervimesine (CT1812), the company’s lead drug candidate. The patent has a natural expiration of 2045. Read the #pressrelease here: buff.ly/HEaUwVa
October is #LewyBodyDementia Awareness Month. Building on last year’s theme of #MorethanMemory, in 2026 we will focus on the concept that #UnderstandingChangesEverything.
Consider the diagnosis. In Lewy body dementias, an accurate diagnosis can be life changing. This is especially true in people living with #DementiaWithLewyBodies (DLB), who may not respond well to medications that are used routinely in others. In fact, some medications that are safe in other people can have dangerous side effects in people with DLB. Understanding, in this case, really does change everything.
#LewyStrong #ClinicalResearch #Dementia #DementiaCare #DementiaSupport
$CGTX announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for October 20th. The objective of this meeting is to align with the FDA on the proposed primary endpoint for a registrational study of zervimesine (CT1812) in people with #DementiaWithLewyBodies (DLB) who experience #hallucination and #delusions. #PressRelease can be found here: buff.ly/z3jcIZt
#Dementia #DementiaSupport #LewyStrong #Psychosis
This year’s World Alzheimer’s Month is focused on the importance of a timely diagnosis. #EarlyDiagnosisMatters. A diagnosis can open the door to resources, support, and therapeutic options.
New diagnostics and disease-modifying treatments for #Alzheimers disease are available, and more are being developed by biotechnology and pharmaceutical companies all over the world. An early and accurate diagnosis can tell you what form of #dementia you have, which in turn can help your neurologist tailor a treatment plan for you. Learn more: alz.org/alzheimers-dementia/…
#DementiaDiagnosisMatters #DementiawithLewyBodies #ENDAlz #LewyStrong #DementiaCare #DementiaSupport #BiotechInnovation #WorldAlzMonth
September 21 is #WorldAlzheimersDay. Today we recognize the 7.4 million Americans and 55 million people worldwide who are living with #Alzheimers disease. Our peers in industry – biotech, pharma, regulators, and healthcare professionals – are all striving towards the same goal of improving the diagnostic and treatment options for people affected by Alzheimer’s and related dementias, be they people living with dementia or the countless care partners who selflessly give their time and energy to their loved ones.
#TogetherWeCan #PlugInToCare #EndAlz #AlzheimersDisease #Dementia #DementiaCare #DementiaSupport #BiotechInnnovation #ClinicalTrials #ClinicalResearch
If you weren't able to see CEO, Lisa Ricciardi present at the #HCW2026 Global Investment Conference, the archive is available on the $CGTX investor page.
Visit ir.cogrx.com/events to learn more about #zervimesine's clinical results, especially those related to neuropsychiatric symptoms, its potential in #DementiawithLewyBodies, and the company's next steps.
#HCWConference #ClinicalResearch #DLBPsychosis #AlzheimersDisease #InvestorConference
According to Alzheimer's Disease International, 35% of carer partners around the world say that they have hidden a loved one's #dementia diagnosis from family. alzint.org/about/dementia-fa…
Let's take a moment during #WorldAlzMonth to educate ourselves and combat the stigma that surrounds #Alzheimers and related dementias. If you or a loved one is living with dementia, there are resources at the Alzheimer's Association and Department of Veterans Affairs to help you tell family and friends.
#MorethanMemory #LewyStrong #DementiaCare #DementiaSupport #EndAlz #DementiaDiagnosisMatters
If you're attending the @HCWCO 28th Annual Global Investment Conference, we invite you to join us in person at 2:30 p.m. on September 15th for CEO Lisa Ricciardi's presentation. If you are unable to attend, the presentation will be available live and archived on the company's investor relations webpage: ir.cogrx.com/events
#HCWConference #BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #DLBPsychosis #AlzheimersDisease #InvestorConference #ThoughtLeadership #BiotechInvesting
September is World Alzheimer’s Month - an internationally coordinated campaign to raise awareness and reduce the stigma of dementias like #Alzheimers disease, #dementia with Lewy bodies, and others. Symptoms of memory loss, agitation, #hallucinations are common yet seldom discussed.
The focus of this year's #WorldAlzMonth is to reduce stigma, increase education, and empower people to discuss their symptoms with their care partners and physicians so everyone can receive an accurate and timely diagnosis.
Take a moment to learn more about dementia today. alzint.org/about/
#EarlyDiagnosisMatters #DementiaDiagnosisMatters #DementiawithLewyBodies #ENDAlz #LewyStrong
Great work from Drs. Mary Hamby and Gary Look as well as the team at PROTEROS biostructures GmbH on elucidating the crystal structure of #zervimesine (CT1812) and illustrating it interaction with neuronal receptors. Read more at ACS Publications: doi.org/10.1021/acsmedchemle….
It's time to rethink neurodegenerative disease.
For decades, diseases like #Alzheimers, #Parkinsons, and #DLB have been diagnosed based on clinical symptoms. However, emerging evidence suggests these aren't discrete disorders but rather points on a complex and interconnected continuum.
In a new article for @NeuroAdvisor, our chief medical officer, Dr. Anthony Caggiano, explores the shift towards a "biology-first" approach.
Read the full article to learn more about the future of neurodegenerative care: neurologyadvisor.com/feature…
#Neurology #BiotechnologyInnovation #AlzheimersDisease #Dementia
Today we presented a poster at #AAIC26 providing support for a Phase 3 program in individuals with #dementia with Lewy bodies (DLB) who experience #psychosis. Learn more about #DLBPsychosis and the neuropsychiatric findings from the #zervimesine Phase 2 'SHIMMER' study by viewing a copy of the poster on our publications webpage: cogrx.com/pipeline/publicati….
#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #LewyBodyDementia #DementiaPsychosis #LewyStrong #Hallucinations #Delusions
It has been great to catch up with #Pentara and our other collaborators and friends at #AAIC26 in London!
#Alzheimersdisease #dementia #AlzheimersResearch #ClinicalTrials #Biostatistics #RegulatoryAffairs
$CGTX CEO, Lisa Ricciardi will join #BRileySecurities analyst, Dr. William Wood for an in-person fireside chat during their Mind, Muscle & Vision Summit. #Pressrelease: buff.ly/csXI6XA The event is being conducted on July 16 at the Intercontinental Boston Hotel.
#BiotechInnovation #ClinicalResearch #DementiaWithLewyBodies #DLBPsychosis #AlzheimersDisaease #InvestorConference #ThoughtLeadership #BiotechInvesting
As we mark Alzheimer's & Brain Awareness Month (#ABAM) this June, it's important to remember that dementia is not a single disease.
#Alzheimers disease, #dementia with Lewy bodies (DLB), vascular dementia, and frontotemporal dementia all present differently - and they all respond differently to treatment.
Interventions appropriate for one type of dementia can be ineffective or harmful to people with another type. An accurate diagnosis is important to ensure safe, appropriate care. Learn more at buff.ly/lVYxMER
#DementiaAwareness #EndALZ #DementiaSupport